Condition

Small Lymphocytic Lymphoma clinical trials and research

• 47Clinical trials
• 1NIH research projects
• 44Countries

Newest Small Lymphocytic Lymphoma clinical trials

All recruiting trials (47)

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

• MK-1045-006: testing a new treatment for B-cell cancers like CLL and SLL

  This trial will test MK-1045 in people with relapsed or treatment‑refractory CLL/SLL to see if it’s safe and how well it works.

  Recruiting at 8 sites Phase 2 Merck Sharp & Dohme LLC · Medellín, Antioquia and 7 other locations · NCT07709000

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Nemtabrutinib and venetoclax in untreated CLL/SLL

  This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07557056

• NX-5948 plus other medicines for B-cell cancers

  This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.

  Recruiting at 5 sites Phase 1/2 Nurix Therapeutics, Inc. · Aurora, Colorado and 8 other locations · NCT07520006

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Venetoclax plus obinutuzumab followed by epcoritamab for untreated CLL/SLL

  This trial tests whether giving venetoclax and obinutuzumab followed by epcoritamab can produce deep remissions in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 6 other locations · NCT07218510

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Mosunetuzumab to clear minimal residual disease in CLL and SLL.

  This trial will try mosunetuzumab, alone or with a BTK inhibitor, to clear minimal residual disease in people with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07052695

• Intermittent versus continuous venetoclax with acalabrutinib in CLL/SLL

  This will test whether giving venetoclax intermittently or continuously together with acalabrutinib helps people with previously untreated CLL or SLL.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07014917

• LP-168 plus obinutuzumab for previously treated and BTK T474I‑mutated CLL/SLL

  This trial tests whether adding LP-168 to obinutuzumab helps people with previously treated CLL/SLL, including those with the BTK T474I gatekeeper mutation, achieve deeper remissions.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06978088

• Comparing a BTK-targeted protein degrader (BGB-16673) with pirtobrutinib for adults with relapsed or refractory CLL or SLL

  This trial tests whether BGB-16673 works better and is as safe as pirtobrutinib for adults whose CLL or SLL has come back or not responded after prior covalent BTK inhibitor treatment.

  Recruiting at 217 sites Phase 3 BeOne Medicines · Birmingham, Alabama and 216 other locations · NCT06973187

• Comparing sonrotoclax combinations versus venetoclax plus rituximab for relapsed or refractory CLL/SLL

  This trial will test whether sonrotoclax combined with obinutuzumab or with rituximab works better than venetoclax plus rituximab for adults whose CLL/SLL has come back or not responded to prior treatment.

  Recruiting at 181 sites Phase 3 BeOne Medicines · Laguna Hills, California and 194 other locations · NCT06943872

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Evaluating Pirtobrutinib for patients with relapsed or refractory CLL/SLL

  This study is testing a new medication called Pirtobrutinib to see if it helps people with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma feel better after they’ve already tried other treatments.

  Recruiting at 125 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 128 other locations · NCT06588478

• Evaluating AZD0486 for treating mature B-cell cancers

  This study is testing a new treatment called AZD0486 to see if it can help people with certain types of mature B-cell cancers feel better and improve their health.

  Recruiting at 56 sites Phase 1/2 AstraZeneca · Boston, Massachusetts and 65 other locations · NCT06564038

• Combining zanubrutinib and obinutuzumab for untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study is testing if combining two medications, zanubrutinib and obinutuzumab, can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma achieve better treatment results.

  Recruiting at 19 sites Phase 2 PETHEMA Foundation · Alicante and 18 other locations · NCT06544785

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Continuing a BTK inhibitor alone versus adding venetoclax for veterans with CLL/SLL

  This will try adding venetoclax for one year to a BTKi in veterans with CLL or SLL who are already responding, to see if they can stop therapy safely compared with staying on BTKi alone.

  Recruiting at 4 sites Phase 2 VA Office of Research and Development · San Francisco, California and 3 other locations · NCT06520098

• Combining pirtobrutinib and venetoclax for treating resistant CLL or SLL

  This study is testing if combining two drugs, pirtobrutinib and venetoclax, can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that hasn’t responded to previous treatments.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06466122

• Treatment for Chronic Lymphocytic Leukemia using modified T cells

  This study is testing a new treatment using modified T cells to see if it can help people with chronic lymphocytic leukemia that hasn't responded to other therapies.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06364423

• Fixed-duration treatment for chronic lymphocytic leukemia with pirtobrutinib and obinutuzumab

  This study is testing a year-long treatment combining two medications, pirtobrutinib and obinutuzumab, to see if it helps people with chronic lymphocytic leukemia feel better.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT06333262

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Using ibrutinib to treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia

  This study is testing if the drug ibrutinib can help adults with chronic lymphocytic leukemia who also have autoimmune hemolytic anemia feel better.

  Recruiting at 3 sites Phase 2 Gruppo Italiano Malattie EMatologiche dell'Adulto · Florence and 2 other locations · NCT05694312

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Vaccination strategy for patients with chronic lymphocytic leukemia

  This study is testing a new vaccination schedule to see if it helps people with chronic lymphocytic leukemia better fight off infections compared to the usual vaccination plan.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05417165

• Comparing early and delayed therapy for high-risk patients with chronic lymphocytic leukemia.

  This study is trying to see if starting treatment right away or waiting longer is better for high-risk patients with chronic lymphocytic leukemia and how it affects their healthcare costs.

  Recruiting at 4 sites Canadian Cancer Trials Group · Vancouver, British Columbia and 5 other locations · NCT05371808

• Acalabrutinib combined with venetoclax or obinutuzumab for treating chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, acalabrutinib with either venetoclax or obinutuzumab, can help people with chronic lymphocytic leukemia who haven't been treated before by reducing cancer cells in their bone marrow.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05336812

• Pirtobrutinib versus ibrutinib for people with CLL or SLL.

  This trial will test whether pirtobrutinib works better or is safer than ibrutinib for adults with CLL/SLL, with a separate part that tries pirtobrutinib alone in treatment‑naïve patients who have a 17p deletion.

  Recruiting at 93 sites Phase 3 Eli Lilly and Company · Anaheim, California and 142 other locations · NCT05254743

• Vaccination for Pneumonia in Patients with Chronic Lymphocytic Leukemia

  This study tests if a pneumonia vaccine can help boost the immune response in people with chronic lymphocytic leukemia and reduce their chances of getting pneumonia.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT05183854

• APG-2575 treatment for patients with relapsed or refractory CLL/SLL

  This study is testing a new oral medication called APG-2575 to see if it can help people with relapsed or hard-to-treat Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

  Recruiting at 4 sites Phase 2 Ascentage Pharma Group Inc. · Guangzhou, Guangdong and 10 other locations · NCT05147467

• Reduced-intensity conditioning to lower treatment-related mortality in stem cell transplant patients

  This study is testing a new way to prepare patients for a stem cell transplant to see if it can lower the risk of serious treatment-related complications.

  Recruiting Phase 2 Thomas Jefferson University · Philadephia, Pennsylvania · NCT05031897

• Exploring BGB-16673 for treating B-cell malignancies

  This study is testing a new drug called BGB-16673 to see if it can safely help people with certain types of B-cell cancers, like Marginal Zone Lymphoma and Follicular Lymphoma, who haven't had success with other treatments.

  Recruiting at 104 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 113 other locations · NCT05006716

• Collecting data on Chronic Lymphocytic Leukemia in Italy

  This study is collecting information from patients newly diagnosed with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B-Cell Lymphocytosis in Italy to better understand these conditions.

  Recruiting at 24 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · Alessandria and 23 other locations · NCT04867915

• Oral treatment with LP-118 for patients with various blood cancers

  This study is testing a new oral treatment called LP-118 to see if it is safe and can help people with certain types of blood cancers that have come back or didn’t respond to other treatments.

  Recruiting at 8 sites Phase 1 Newave Pharmaceutical Inc · Chicago, Illinois and 7 other locations · NCT04771572

• Intermittent dosing of ibrutinib for advanced chronic lymphocytic leukemia

  This study is testing if taking the cancer drug ibrutinib in a 'ON-OFF' way can help people with advanced chronic lymphocytic leukemia stay healthy while possibly having fewer side effects and lower costs.

  Recruiting at 6 sites Phase 1/2 Karolinska University Hospital · Trondheim and 8 other locations · NCT04771507

• Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT04545762

• APG-2575 treatment for relapsed/refractory CLL/SLL

  This study is testing a new treatment called APG-2575, both alone and with other medications, to see how well it works for people with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

  Recruiting at 17 sites Phase 1/2 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 17 other locations · NCT04494503

• Early treatment for high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study tests if starting treatment early with venetoclax and obinutuzumab can help people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma live longer and feel better compared to waiting until symptoms show up.

  Recruiting at 299 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 632 other locations · NCT04269902

• Evaluating the safety of azer-cel in patients with relapsed/refractory B-cell cancers

  This study is testing a new treatment called azer-cel to see if it is safe and effective for adults with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 15 sites Phase 1 Imugene Limited · Tampa, Florida and 14 other locations · NCT03666000

• Acalabrutinib with or without Obinutuzumab for early-stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  This study is testing whether a new drug called acalabrutinib, alone or with another drug called obinutuzumab, can help people with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT03516617

• Hematopoietic stem cell transplant for blood cancers

  This study is testing two different ways of doing stem cell transplants for people with blood cancers to see which method works better and is safer.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03314974

• Observing the natural history of certain blood cancers

  This study is tracking how certain blood cancers develop over time in patients to learn more about them and find new treatment options.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00923507

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Evaluating the addition of Venetoclax for treating chronic lymphocytic leukemia.

  This study is looking at whether adding Venetoclax to the treatment for people with chronic lymphocytic leukemia who are already doing well on another medication can make the treatment work better and cause fewer side effects, all while helping improve your quality of life.

  NIH research Kansas City VA Medical Center · Kansas City, United States · NIH-10801637

Related topics

Quick answers

How many Small Lymphocytic Lymphoma clinical trials are recruiting right now?

47, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 44 countries. The most sites are in United States (39 trials), Spain (9 trials), Australia (8 trials), Italy (8 trials), China (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 23, Phase 1/2: 8, Phase 3: 6, Phase 1: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →